1stOncology™: Cancer Intelligence Service – Page 8211 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Gennao Bio Announces Abstract Accepted for Poster Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

On September 30, 2021 Gennao Bio, a privately-held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, reported that an abstract reporting preclinical results for its proprietary, non-viral gene monoclonal antibody (GMAB) nucleic acid delivery system has been selected for a poster presentation at the 2021 AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper), hosted by the American Association for Cancer Research (AACR) (Free AACR Whitepaper), the National Cancer Institute (NCI), and the European Organization for Research and Treatment of Cancer (EORTC) (Press release, Gennao Bio, SEP 30, 2021, View Source [SID1234590598]). The conference will be held virtually from October 7, 2021 to October 10, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Gennao’s GMAB technology platform utilizes a novel, cell-penetrating antibody to non-covalently bind to and deliver therapeutic levels of multiple types of nucleic acids including messenger ribonucleic aid (RNA), synthetic RNA, RNA interference, deoxyribonucleic acid, antisense oligonucleotides and gene editing molecules. Gennao Bio is developing this delivery system with an initial focus on oncology and monogenic skeletal muscle diseases.

The details of the presentation are as follows:

Title: Systemic targeting of medulloblastoma using a cell-penetrating, nucleic acid binding, monoclonal antibody.
Poster Number: P135
Authors: Elias Quijano, Min Soo Kwang, Bruce C. Turner, Stephen Squinto, Ranjit Bindra, W. Mark Saltzman and Peter M. Glazer.

The full abstract and poster presentation can be accessed on the AACR (Free AACR Whitepaper)-NCI-EORTC annual meeting website beginning October 7, 2021 at 9:00 a.m. ET.

IMV’s DPX Delivery Technology to be Showcased in Two e-Posters at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics

On September 30, 2021 IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, reported that two abstracts featuring two DPX-based immunotherapies have been accepted for virtual poster presentation at the upcoming AACR (Free AACR Whitepaper)-NCI-EORTC Virtual AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) on October 7-10, 2021 (Press release, IMV, SEP 30, 2021, View Source [SID1234590597]).

Poster #1:

Survivin peptides formulated in the DPX delivery platform rather than standard emulsions, elicit a robust, sustained T cell response to survivin in advanced and recurrent ovarian cancer patients.

Presenter:
Yogesh Bramhecha, Ph.D.,
Director of Translational Research, IMV Inc.

Poster Number:
LBA026

Poster #2:

DPX-SurMAGE, a novel dual-targeted immunotherapy for bladder cancer, induces target-specific T cells with a favorable safety profile in preclinical model.

Presenter:
Yves Fradet, M.D.

Professor, Department of Surgery

Faculty of Medicine, Université Laval, Quebec City

Poster Number:
LBA030

Full abstracts and e-posters will be available on demand on the conference platform on October 7, 2021 at 9am ET. Both e-posters will be available under the Scientific Publications & Posters section on IMV’s website.

Immunome to Present Preclinical Data on Anti IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

On September 30, 2021 Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, reported that it will be making an oral poster presentation on the company’s anti IL-38 antibody program at the upcoming joint meeting of the 2021 AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper), being held October 7-10, 2021 (Press release, Immunome, SEP 30, 2021, View Source [SID1234590596]).

Presentation Details:

Title: "IMM20324, a first-in-class, anti-interleukin-38 monoclonal antibody, rescues myeloid cell activation in vitro and induces robust anti-tumor responses in vivo."

Authors: John P. Dowling, et al.

Abstract Number: LBA022

Date/Time: All poster presentations are made available by the conference at the opening of the meeting on October 7, 2021, at 9:00am E.T.

Tango Therapeutics Announces Presentation of Preclinical Data on Lead Program and Discovery Platform in Five Abstracts Accepted at AACR-NCI-EORTC 2021

On September 30, 2021 Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported that five abstracts have been selected for presentation as virtual posters at the AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) on October 7 – 10, 2021 (Press release, Tango Therapeutics, SEP 30, 2021, View Source [SID1234590595]).

"The preclinical data being presented today highlight the potential applicability of synthetic lethal drug targeting across a range of cancer types. As an example, our lead program, TNG908, an MTA-cooperative PRMT5 inhibitor selective for cancers with deletion of the MTAP gene, shows strong regressions across multiple types of cancer," said Barbara Weber, M.D., president and Chief Executive Officer of Tango Therapeutics. "We look forward to leveraging these data to inform our planned clinical development program."

Dr. Weber will also be co-chairing an Educational session titled "Exploiting Synthetic Lethality" on October 7, 2021 at 10:00 AM ET.

Details on Tango’s presentations at AACR (Free AACR Whitepaper)-NCI-EORTC are as follows:

Poster Title: MTAPnull-selective PRMT5 inhibitors drive regressions in MTAP-deleted xenograft models across histologies
Abstract #: P214
Date and Time: October 7, 9:00 AM ET

Poster Title: VRK1 is a novel synthetic lethal target in VRK2-methylated glioblastoma
Abstract #: P182
Date and Time: October 7, 9:00 AM ET

Poster Title: CRISPR screens identify sensitizers to Trametinib in KRAS mutant cancer cell lines
Abstract #: P183
Date and Time: October 7, 9:00 AM ET

Poster Title: Loss of HS2ST1 cooperates with MAPK inhibition to impair growth of mesenchymal KRAS mutant NSCLC
Abstract #: P146
Date and Time: October 7, 9:00 AM ET

Poster Title: Isogenic CRISPR Anchor Screens identified actionable nodes to CHK1/2 inhibitor Prexasertib in TP53 mutant cancer
Abstract #: P095
Date and Time: October 7, 9:00 AM ET

CatalYm To Present Update From GDF-15 Targeting First-in-Human I/O Clinical Trial in Plenary Session at AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics

On September 30, 2021 CatalYm reported that a data update from their ongoing first-in-human trial "GDFather" (GDF-15 Antibody-mediated Effector cell Relocation) has been accepted for oral presentation at the 2021 AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) (Press release, Catalym, SEP 30, 2021, View Source [SID1234590594]). The conference will be held virtually from October 7 -10, 2021.

"GDF-15 is frequently overexpressed in various tumor types and appears to play a central role in suppressing several key mechanisms by which the immune system recognizes and eliminates tumors, making it an exciting target in immuno-oncology drug development. We look forward to presenting an update from this trial to the scientific community in an oral plenary session," said Eugen Leo, MD, PhD, MBA, Chief Medical Officer at CatalYm.

Details of the oral presentation:

Presentation title: A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced stage solid tumors

Session title: New Drugs on the Horizon II

Speaker: Eugen Leo, MD, PhD, MBA, Chief Medical Officer of CatalYm

Date/time: October 9, 2021, at 4.05 pm ET/22.05 pm CEST

About the GDFather Trial

The ongoing first-in-human GDFather trial (GDF-15 Antibody-mediaTed Effector cell Relocation) is a two-part, open-label study to evaluate GDF-15 inhibitor CTL002 in advanced, checkpoint inhibitor refractory or relapsed solid tumor patients. In the dose escalation phase (Part A), up to 24 patients will receive escalating doses of CTL-002 in a "3+3" manner with the lead candidate given as a monotherapy and followed by combination with an anti-PD-1 checkpoint inhibitor. In the second dose expansion phase (Part B, phase 2a), several cohorts with tumors identified to be GDF-15-dependent will be treated to further evaluate safety and preliminary efficacy of CTL-002 treatment.

About CTL-002

CTL-002 is a humanized, monoclonal antibody designed to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15). GDF-15 secretion by the tumor has been shown to prevent T cell migration into the tumor and suppresses T cell function and the adaptive immune response in the tumor microenvironment. All these mechanisms help the tumor evade the immune system and become resistant to standard of care and current immunotherapy approaches such as checkpoint inhibitors. CTL-002 counteracts these immuno-suppressive mechanisms by neutralizing GDF-15, enhancing the infiltration of immune cells into the tumor, improving both priming of T cells by dendritic cells and tumor killing by T cells and NK cells.